Global /China /Healthcare /Medical Devices /300406
chevron_leftBack
Beijing Strong Biotechnologies,Inc. logo

Beijing Strong Biotechnologies,Inc.

300406
SHE: 300406 Delayed
12.70CNY 2.6%
1.88 USD
As of 16 June 2026, Beijing Strong Biotechnologies,Inc. has a market cap of $1.1B USD, ranking #10201 globally and #2829 in China. It ranks #898 in the Healthcare sector, and #181 in the Medical Devices industry.
Global Rank
10201
Country Rank
2829
Sector Rank
898
Industry Rank
181
Key Stats
Market Cap
$1.1BUSD
7.43B CNY
Enterprise Value
$1.16BUSD
7.84B CNY
Revenue (TTM)
$202.4MUSD
1.37B CNY
EBITDA (TTM)
$83.87MUSD
567.6M CNY
Net Income (TTM)
$31.34MUSD
212.22M CNY
EBITDA Margin
41%
Profit Margin
15%
PE Ratio
35.4
PS Ratio
5.4
PB Ratio
1.9
EV/EBITDA
13.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Hongjun Liang open_in_new
Employees
1,098
Founded
2001
Website
bsbe.com.cn open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
2.6% 8.2% 6.5% -4.7% -6.1% -8.7%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300406
北京九强生物技术股份有限公司 Class A
ISIN: CNE100001Y26
Shares Out.:
586.309M1 Shares Float: 330.533M2
TV:
SA:
YF:
GF:
BA:
MS:
12.70 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Beijing Strong Biotechnologies,Inc.

Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. The company offers biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombin III, von Willebrand factor antigen, protein S activity, protein C, lupus anticoagulant, fibrin degradation products, and d-dimer. It also provides blood grouping card comprising ABO blood type anti stereotype detection card, DiaClon ABD-confirmation, and DiaClon ABO/D+ reverse grouping for patients; and automatic coagulation analyzer, automatic biochemistry analyzer, fully automatic chemiluminescence immunoassay analyzer, and automated blood groupings analyzer. In addition, the company provides technology and document services. It sells its products under the GCELL and Beijing MDC brands. The company was founded in 2001 and is based in Beijing, China.

Similar Companies

Industry: Medical Devices (China)
Name
Market Cap diff.
PE
$30.08B
203.66B CNY
3K%
26.0
$13.62B
92.23B CNY
1K%
48.5
$5.61B
38.02B CNY
412%
23.4
$5.53B
37.43B CNY
404%
52.7
688617
$5.04B
34.14B CNY
360%
39.6
$4.56B
30.86B CNY
316%
13.7
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
16K%
25.8
$160.73B
15K%
56.7
$159.07B
14K%
25.6
DHR
$126.55B
11K%
34.7
SYK
$120.69B
11K%
38.3
MDT
$101.9B
9K%
22.2
chevron_leftBack